Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Cool summer, another wave of blue storm
Time Posted：2023-08-21 17:00
Yi Ke Tie® Dexamethasone Acetate Oral Mucosal Adhesive Tablets
Levosalbutamol represents not only a change in name, but also a new direction.
Time Posted：2020-07-09 21:51
Time Posted：2020-03-20 11:38
Why is my talkative friend so silent today? Why is my foodie colleague indifferent to delicious food? Why is the aloof male god groaning secretly in an empty place? Behind all this, is it the distortion of human nature or the collapse of morality? Welcome to today's science popularization and decryption program - "Uninvited Guests in the Oral Cavity" 1. What is oral ulcer? The oral cavity is the starting point of the digestive tract. In addition to consciously ingesting controllable substances such as food and water, people generally do not allow other things to pass through the oral cavity, let alone stay there. Oral ulcer is such an "uninvited guest" that resides in the oral mucosa. Oral ulcers are common on the inner side of the lips, palate, and cheek, appearing as round or oval painful ulcer points. (Note: This article analyzes oral ulcers mainly as "recurrent aphthous ulcers", also known as aphthous ulcers. It is different from "one-time" traumatic oral ulcers and oral ulcers accompanied by diseases. The difference is whether it recurs frequently.) Uninvited, it is naturally a bad guest. The obvious pain constantly reminds people that this "guest" is not easy to deal with, and even slight collision or contact with the wound will make the pain more intense. Words are not beautiful, food is not fragrant, it is really painful. What's even more painful is that oral ulcers are also a "permanent" disease. It is said to be "permanent" because of its incidence and recurrence. According to the "Diagnosis and Treatment Guidelines for Recurrent Aphthous Ulcers (Trial)" issued by China in 2012: 10%-25% of the population suffer from recurrent aphthous ulcers, and the most common age is 10-30 years old. It can occur in all seasons and at any time of the day. Therefore, it presents a frustrating situation: people who do not have oral ulcers basically do not get them. However, people who have had oral ulcers often have repeated attacks. The pain cannot be described, nor can it be understood. 2. Causes of the disease The cause of recurrent aphthous ulcers is still unclear, but many inducing factors have been identified. One is genetic factors. If you often have oral ulcers, you might ask your parents. Their history of ulcers may be richer than yours. Second, immune factors. When immunity decreases, pathogens take advantage of the weakness, and symptoms appear in the oral cavity as oral ulcers. Third, dietary factors. Partial diet can lead to a lack of trace elements such as iron, zinc, folic acid, and vitamin B in the body, thus causing oral ulcers. Fourth, psychological factors. When people are under great mental stress, they are prone to negative emotions such as irritability and anxiety, poor sleep quality, which reduces the body's immune function and thus causes oral ulcers. 3. Treatment methods Knowing the cause of the disease often allows for targeted treatment. Liu Hong, chief physician of Peking University School of Stomatology, believes that the treatment of recurrent aphthous ulcers mainly focuses on local anti-inflammation, relieving oral pain, and promoting ulcer healing, while systemic treatment aims to prolong the interval. I believe everyone can see the helplessness behind this treatment method - that is, it can only treat the symptoms, not the root cause. The cause of recurrent aphthous ulcers has not yet been fully elucidated, and we can only remove many interfering factors and find several key branches on the main trunk of the truth. And these branches are difficult to prune: genetic factors are difficult to solve with the current medical level; immune factors are attributed to physique, and improving physique is a long-term process; as for dietary and psychological factors, for the high-incidence population, namely the 10-30 age group, whether it is the pressure of study or work, or the lifestyle of young people who do not pay attention to "health preservation", it is difficult to achieve effective and long-term changes. Do you want this group of people to improve their lifestyle - not staying up late playing games, chasing dramas, not working overtime, having a nutritious meal every day? Fried chicken and cola are not fragrant? Zhu Yilong and Li Xian are not handsome? Overtime is not happy? So the disease will always come. The essence of punk health preservation is to maintain health while killing oneself! This is a helpless reality, but fortunately, recurrent aphthous ulcers are self-limiting, that is, they usually heal on their own in about a week. However, no one wants to keep it for a second longer, because it harms an important organ for human survival and social interaction - the oral cavity. Words are not beautiful, food is not fragrant, it is really painful. In summary, the best way to treat oral ulcers is still to "treat the symptoms, not the root cause". Since a fundamental solution has become a luxury, being able to shorten the duration of the disease and reduce pain has become an excellent treatment method. Topical medication has emerged, such as the well-known Yikote, the oral ulcer patch with a cute pill image of Yikozai. Its pills also thoughtfully adopt a double-layer structure, with the yellow side protecting the wound from contact, and the white side releasing the efficacy for rapid treatment. Gently apply the small pill to the ulcer, and the pain can be relieved in 5 minutes, and the effect lasts for 3 hours. It adheres firmly and does not affect eating and drinking, and basically two pills can heal oral ulcers. In the shortest time, it solves both the pain problem and the eating and drinking problem. It makes the biggest troubles of oral ulcers easily solved. Of course, fundamentally solving oral ulcers is the goal pursued by medicine. It is believed that with the advancement of time and technology, the last layer of fog will surely be lifted, which is the charm of human medicine.
In search of the most beautiful pharmacists: A tribute to every member of the pharmacy team
Time Posted：2020-03-17 11:47
Work is like dust, dedication is like fire. Heroes are not necessarily on high mountains; they are among the people, or rushing towards the people. During the raging epidemic, everyone is working hard at their respective posts. Medical workers are rushing to the front line to fight the virus, and others are shining brightly on the "invisible front line." They are road cleaners, logistics transporters, and traffic guards. In pharmacies, there is a group of brave and fearless women who bid farewell to their families every day and resolutely rush to their posts to provide health security for everyone. They are the "pharmacy people." In the face of the epidemic, they seamlessly switch between their roles as family pillars and work responsibilities, protecting the health of their customers and families, showing great love in adversity, and fully demonstrating their gentle yet strong feminine power. Their strength deserves to be seen. She, Liang Minli from Dacanlin Pharmacy in Nanning, Guangxi, unloaded goods with her colleague until 1 a.m. to ensure that epidemic prevention materials could be delivered to the store in time. After a short nap, she tirelessly delivered the materials to more than a dozen stores in the city and surrounding areas. By the time she returned to the city, it was already dark. But Liang Minli felt it was all worthwhile knowing that the materials had arrived on time. She, Su Lijun from Haiwang Xingchen Pharmacy in Shenzhen, resolutely gave up her return ticket and volunteered for overtime after receiving the notice of the epidemic outbreak. Su Lijun said that although she couldn't go home to accompany her family, she felt warm and comforted seeing that customers could buy masks, seeing kind customers actively helping with the goods, and especially seeing her colleagues working together to fight the epidemic. She, Zou Taorong from Hunan Yifeng Pharmacy, proactively delivered medicine to a customer whose family member was upset due to home quarantine. One day, she met a special customer, Xiao Wang, who, after buying epidemic prevention supplies, mentioned that his mother often suffered from insomnia and anxiety due to the epidemic. After listening to his description, Zou Taorong sent Xiao Wang's mother some calming oral liquid. Soon, Xiao Wang returned with a letter of praise, but Zou Taorong said that as long as Xiao Wang's mother could sleep well, it was the greatest praise for her. There are many more stories like those of Liang Minli, Su Lijun, and Zou Taorong. They all work diligently on the front line of pharmacies, silently striving. Jingxin has been focusing on women's health for 22 years. This is not only the initial intention of the Jingxin brand but also a mission that Jingxin has been upholding. Jingxin hopes that every woman living in this great era will have her own story and attitude. Therefore, during the epidemic, when everyone focuses on the great heroes on the high mountains, Jingxin hopes that the pharmacy people fighting on the front line can also be seen. In particular, the feminine beauty they demonstrate in the context of the great epidemic should be conveyed and felt. Therefore, Jingxin focuses on the stories and perspectives of pharmacy people, exploring the feminine power they represent in this great era, showcasing it to the public, and paying tribute to the professional attitude of pharmacy people in safeguarding health. This is also the "focus on women's health" that the Jingxin brand has always advocated—not only care for physical health but also affirmation and commendation of women's strength. To this end, on Women's Day, March 8th, Jingxin, together with pharmacies nationwide, officially launched the "Her Power: Finding the Most Beautiful Shop Assistants" recruitment activity. It collects true stories of pharmacy people who persevere on the "invisible front line" and selects the shop assistants who best represent the female "Her Power," conveying this extraordinary "Her Power" displayed in ordinary positions. Currently, the "Her Power: Finding the Most Beautiful Shop Assistants" activity is still underway, with more than 40 pharmacies participating. The national voting will officially start on March 16th. If you also want to pay tribute to them, if you also want to convey this "Her Power," please scan the QR code on the poster immediately to watch the most beautiful stories and vote for the most beautiful shop assistants!
Time Posted：2020-02-20 21:58
In China, multinational pharmaceutical giants have long held over 90% of the market for inhalation preparations related to respiratory diseases. This market has always been called the "highest-end and most difficult segment in the generic drug field." Between 2016 and 2018, after the implementation of the new chemical drug registration regulations, the National Medical Products Administration (NMPA) only approved six inhalation preparations for the first time, all of which were registered under the old six categories and required re-evaluation for consistency after approval. On April 9 this year, HealthGen's "Shutanlin" (ipratropium bromide and salbutamol inhalation solution) was approved for marketing. The launch of "Shutanlin" has milestone significance for the R&D of domestic generic inhalation preparations, and its appearance will usher in a new pattern for the domestic inhalation preparation market. The reason is that "Shutanlin" is the first drug to pass the consistency evaluation among all respiratory disease-related inhalation preparations, and the first nebulized inhalation solution approved for registration under the new four categories in China. So, what are the reasons for the successful R&D and launch of "Shutanlin"? Strong capital is an important driving force for R&D. Founded on December 18, 1992, and listed on the Shanghai Stock Exchange in June 2001, HealthGen, which is committed to becoming a leader in China's big health industry, consists of Lizhu Pharmaceutical and HealthGen Pharmaceutical. Its business involves more than 500 varieties in multiple fields, including chemical preparations, raw materials, diagnostic reagents, monoclonal antibodies, and health products. It is a comprehensive group company integrating R&D, production, sales, and services of pharmaceuticals and health products. By the end of 2018, the company's total assets reached RMB 24.986 billion, and it was included in the "Top 100 Chinese Chemical Pharmaceutical Enterprises in 2018" Top 10! Since 2013, HealthGen has conducted in-depth research on respiratory drugs and invested a large amount of funds in R&D, with cumulative R&D investment exceeding 100 million yuan. Excellent scientific research configuration is a strong backing for R&D. Also in 2013, HealthGen Group joined forces with a leading domestic R&D team headed by Professor Jin Fang, a leading figure in China's respiratory preparation research and a current professional committee member of the Chinese Pharmacopoeia Commission, to establish Shanghai Fanyu Health Pharmaceutical Technology Co., Ltd., forming a research service platform for respiratory system drugs with first-class technical level in China. In 2015, a joint venture was established with the Guangzhou Institute of Respiratory Diseases led by Academician Zhong Nanshan to establish Guangzhou HealthGen Respiratory Drug Engineering Technology Co., Ltd., dedicated to the R&D of inhalation preparations. Currently, HealthGen Group has more than 20 inhalation preparation products under development. On the one hand, it is a powerful comprehensive pharmaceutical group, and on the other hand, it is a domestic R&D team that masters high-end technical thresholds. This story of the collision between technology and capital begins with "Shutanlin." As a milestone drug for inhalation preparations, the launch of "Shutanlin" has broken the long-standing technological monopoly of original products in China. At the same time, as a compound preparation, "Shutanlin" contains 2.5mg salbutamol and 0.5mg ipratropium bromide per bottle of nebulized solution. The golden ratio of 5:1 provides a more convenient and safer medication option for patients with COPD, asthma, and other airway obstructive diseases. It is believed that after "Shutanlin," HealthGen Group will become more stable in the innovation and R&D of inhalation preparations. The series of upcoming inhalation preparation products are also highly anticipated! Source: Pharmaceutical Cube
What makes Health Yuan's "Shutanlin", a generic drug, different?
Time Posted：2020-02-20 21:57
As a preferred treatment method for obstructive airway diseases recommended by domestic and international guidelines, inhalation therapy is the mainstream clinical treatment method. However, due to the high barriers to the development of inhalation preparations, there are relatively few players in China with the ability to participate in research and development. In this peak competition, in April 2019, HealthGen Group broke the long-standing technological monopoly of original research products in China by launching the first respiratory disease inhalation preparation to pass consistency evaluation and the first new Class 4 registered and approved nebulized inhalation solution - Compound Ipratropium Bromide Inhalation Solution (Shutanglin). So, what is different about HealthGen's Compound Ipratropium Bromide Inhalation Solution (Shutanglin)? Stability is comparable to that of the original research product, and the content of related substances (impurities) is lower. Compound Ipratropium Bromide Inhalation Solution (Shutanglin) adopts the currently internationally leading blow-fill-seal aseptic manufacturing technology and strictly controls product quality according to European and American quality requirements. Drug stability tests show that the change trend of related substances (impurities) of the drug is consistent with that of the original research product, and the product quality and stability are comparable to that of the original research product, with a lower content of related substances (impurities). Under the same administration time and dosage, the total amount of drug inhalation is comparable to that of the original research product. Compound Ipratropium Bromide Inhalation Solution (Shutanglin) is composed of ipratropium bromide and salbutamol, which can simultaneously act on different targets in bronchodilation, rapidly dilating the main bronchi and bronchioles, and has the characteristics of rapid effect, strong effect, safety, and convenience. According to the relevant provisions of the Chinese Pharmacopoeia and the European Pharmacopoeia, the fine particle dose of the nebulized aerosol of the inhalation solution is determined to evaluate the aerodynamic particle size distribution of Compound Ipratropium Bromide Inhalation Solution (Shutanglin) and the original research product. The results show that the aerodynamic particle size distribution of ipratropium bromide and salbutamol is consistent with that of the original research product, and the total amount of drug inhalation under the same administration time and dosage is comparable to that of the original research product. As the leader in this peak competition, "Shutanglin" is just the beginning. Currently, HealthGen Group has more than 20 inhalation preparations under research and development, and a series of upcoming inhalation preparations will also help HealthGen become the winner of this peak competition. Source: Medical Pulse Pediatrics
The first domestically approved
Time Posted：2020-02-20 21:53
On September 27, 2023, Health Yuan's subsidiary, Shenzhen Tai Tai Pharmaceutical Co., Ltd., obtained approval from the National Medical Products Administration (NMPA) for its new Class 3 registration application of levalbuterol hydrochloride nebulization solution, becoming the first levalbuterol preparation (trade name: Lishutong) to be launched in China. The incidence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) in China continues to increase, with patients accounting for as much as one-tenth of the total population. However, due to a general lack of patient awareness, the diagnosis and standardized treatment rates remain severely low. Currently, nebulization therapy is a commonly used method of drug administration for patients with respiratory diseases. However, according to IMS data, in 2018, foreign pharmaceutical companies occupied 91% of the Chinese market for nebulization drugs. Due to the high R&D threshold in the field of nebulization preparations, there are almost no better domestic alternatives. Health Yuan's newly approved levalbuterol hydrochloride nebulization solution (Lishutong) is expected to break the deadlock of the nebulization drug market being highly monopolized by foreign pharmaceutical companies, and also provides domestic doctors with more choices in the field of respiratory disease medication. It is worth noting that on June 6, 2018, the list of drug registration applications included in the priority review procedure by the NMPA's Center for Drug Evaluation (CDE) (29th batch) included three pediatric drugs, and Health Yuan's levalbuterol hydrochloride nebulization solution was among them. From the inclusion in the priority review procedure application, it took the NMPA only one year and two months to approve Lishutong for listing, indicating the urgent market demand for the drug and highlighting the profound technical R&D background of Health Yuan's R&D team. Foreign companies monopolize 91% of inhalation preparations. A Ping An Securities research report in June this year stated that chronic respiratory diseases are the third leading cause of death from chronic diseases among Chinese residents: China's chronic disease mortality rate reached 533/100,000 in 2012, with chronic disease deaths accounting for 86.6%, of which the mortality rate from chronic respiratory diseases was 68/100,000, accounting for 12.8%, making it the third leading cause of death from chronic diseases after cardiovascular and cerebrovascular diseases and tumors. According to statistics from the Ministry of Health, the incidence of respiratory diseases in China accounts for about 6.94% of the total incidence, with 150 million people suffering from various respiratory diseases every year. In the face of a patient population of over 100 million, there are few treatment methods, and the treatment drugs are not only limited in variety but are also mainly in the hands of foreign pharmaceutical companies. Asthma, as a chronic inflammatory disease, can be controlled by long-term use of corticosteroids, while the treatment of acute exacerbations of asthma and COPD is centered on bronchodilators, mainly to relieve bronchospasm and improve ventilation, with some overlap in medication. In terms of dosage forms, inhalation dosage forms have gradually become mainstream. According to research reports, the global market size for asthma and COPD drugs exceeded US$45 billion in 2017, with the inhalation preparation market reaching US$37 billion. Blockbuster products have frequently emerged in this field, with the average sales of the top 10 products in the United States in 2017 being around US$2 billion. The report also analyzes that the current domestic market for asthma and COPD drugs is approximately 17 billion yuan, with a CAGR of 14% from 2012 to 2018, of which foreign companies account for 78%, and inhalation dosage forms account for 67%. Among inhalation dosage forms, foreign companies account for 93%, with AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline (GSK) accounting for 91% of the market. For example, Seretide is GSK's best-selling inhaled asthma or COPD drug, but it lost its US patent protection in 2010. Even years after the patent expired, it has not been affected by generic drugs, mainly because Seretide is a combination product of a drug and an inhaler. The production process of this combination product is relatively complex, and it is more challenging to develop than solid oral dosage forms such as tablets. The US FDA only approved the first generic drug for Seretide in February this year. The NMPA has indeed approved many inhalation preparations before, but they were all approved before the implementation of the new chemical drug registration classification. According to information from the Pharmaceutical Cube database, between 2016 and 2018, before the approval of Health Yuan's Shutanlin (inhalation compound ipratropium bromide solution), the NMPA only approved six inhalation preparations for the first time, and all of them were registered under the old Class 6 system. Four of them were inhalation acetylcysteine solutions for expectoration, which still need to undergo consistency evaluation after approval (see: Health Yuan's "inhalation compound ipratropium bromide solution" becomes the first generic drug to be launched, opening up a major change in the domestic inhalation preparation market). Lishutong® accelerates the domestic substitution of inhalation preparations. On April 3, 2018, the General Office of the State Council issued the "Opinions on Reforming and Improving the Supply Guarantee and Use Policies for Generic Drugs" (hereinafter referred to as the "Opinions"), which focuses on three important directions for generic drugs: first, promoting the R&D of generic drugs, focusing on solving the shortage of high-quality generic drugs; second, highlighting problem orientation and improving the quality and efficacy of generic drugs; and third, improving supporting policies and promoting the rapid entry of high-quality generic drugs into clinical use. In fact, the layout of high-quality domestic pharmaceutical companies in the field of high-difficulty generic drugs is far ahead of the current policy support. As early as 2013, Health Yuan Pharmaceutical Group Co., Ltd., relying on its strong technical R&D background, focused on the layout and is committed to becoming a leading brand in the field of respiratory nebulization therapy. Six years later, Health Yuan's layout began to bear fruit. In April this year, it launched the first new Class 4 registered and approved nebulization solution in China—Shutanlin® (inhalation compound ipratropium bromide solution). This is also the first drug in nebulization preparations that is considered to have passed consistency evaluation. At the same time, for the NMPA, this means that the registration and approval path for inhalation solution preparations with higher standards (chemical drug registration classification reform work plan) has been opened up, and the CDE will have more experience in the subsequent approval of varieties. On September 27, Health Yuan launched another first in China—the first new Class 3 registered and approved nebulization solution, Lishutong® (levalbuterol hydrochloride nebulization solution), which also became the first levalbuterol to be launched in China. Compared with ordinary salbutamol, Lishutong® has the characteristics of fewer side effects, better efficacy, and smaller dosage. First, Lishutong® removes the dextrorotatory isomer, which has higher β1 receptor selectivity and can produce side effects; it only contains the levorotatory active ingredient with higher β2 receptor selectivity, resulting in a lower incidence of side effects; second, it improves FEV1 more than salbutamol, promotes symptom improvement, and reduces hospitalization rates; third, 0.63 mg of levalbuterol has the same efficacy as 2.5 mg of salbutamol. The successive launches of Shutanlin® and Lishutong® mean that Health Yuan has the ability to produce high-end generic inhalation preparations, and the monopoly position of imported companies will be broken. Domestic companies such as Health Yuan are actively deploying in blockbuster products, and once the first generic drug is successful, they are expected to quickly achieve import substitution. Regarding the successful launch of Lishutong®, Health Yuan stated: "The company has always used 'Healthy Breathing, Yuan Qi You Wo' as its slogan in the respiratory field. This not only means that Health Yuan will take 'becoming a leading brand in the field of respiratory nebulization preparations' as its vision, but also hopes to produce high-quality domestic drugs, provide Chinese doctors with more and better choices, and allow more asthma and COPD patients to receive better diagnosis and treatment." Source: Pharmaceutical Cube
Time Posted：2020-02-19 21:59
In China, multinational pharmaceutical giants have long held over 90% of the market for inhalation preparations related to respiratory diseases. This market has always been called the "highest-end and most difficult segment in the generic drug field." This year, Joincare Pharmaceutical Group Industry Co., Ltd.'s "Shutanlin" (compound ipratropium bromide solution for inhalation) was approved for marketing. The launch of "Shutanlin" has milestone significance for the R&D of domestic generic inhalation preparations, and its appearance will lead a new pattern in the domestic inhalation preparation market. On September 6, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Healthy Yuan Group") held a grand new product launch satellite meeting themed "Healthy Breathing, Yuan Qi You Wo" at the Wuhan International Conference Center. Professor Huang Mao, director of the Respiratory Department and Respiratory Disease Research Institute of Jiangsu Provincial People's Hospital; Professor Song Yuanlin, director of the Respiratory and Critical Care Medicine Department of Huashan Hospital Affiliated to Fudan University, and doctoral supervisor; and Professor Cui Yongyao, from the Department of Pharmacology, Shanghai Jiao Tong University School of Medicine, attended the meeting and delivered wonderful speeches. As the first inhalation preparation approved by Healthy Yuan Group, the appearance of "Shutanlin" (compound ipratropium bromide solution for inhalation) at this meeting allowed nearly 10,000 respiratory-related clinicians from across the country to learn about this drug, the first in China to pass consistency evaluation and the first new Class 4 registered and approved nebulized inhalation solution, for the first time through the introduction of authoritative experts. It is reported that the launch of "Shutanlin" has milestone significance for the R&D of domestic generic inhalation preparations: Currently, chronic respiratory diseases have become the third leading cause of chronic disease death in China. However, due to the high barriers to R&D, approval, and production of inhalation preparations, this market in China has long been dominated by foreign companies. In order to seize the development opportunities in the respiratory system drug market, Healthy Yuan Group conducted in-depth research in this field, establishing Shanghai Fangyu Healthy Pharmaceutical Technology Co., Ltd., with Professor Jin Fang, a member of the Chinese Pharmacopoeia Commission and former director of the Shanghai Respiratory System Drug Engineering and Technology Research Center of the Shanghai Pharmaceutical Industry Research Institute, at its core. It also jointly established Guangzhou Healthy Yuan Respiratory Drug Engineering and Technology Co., Ltd. with the Guangzhou Institute of Respiratory Diseases, presided over by Academician Zhong Nanshan of the Chinese Academy of Engineering, an expert in respiratory diseases and a medical authority, investing heavily in the R&D of respiratory system drugs and accumulating rich experience in inhalation preparation technology. On April 9 this year, Healthy Yuan Group announced that it had received the "Drug Registration Approval Document" issued by the National Medical Products Administration, and "Shutanlin" (compound ipratropium bromide solution for inhalation) was approved for marketing as a new Class 4 registration application. Previously, only Boehringer Ingelheim's original "Tiotropium" was on sale domestically, and Healthy Yuan Group is the first generic manufacturer. It can be said that the launch of "Shutanlin" meets the needs of many domestic patients to use high-quality domestic drugs. It is worth mentioning that Professor Cui Yongyao from the Department of Pharmacology, Shanghai Jiao Tong University School of Medicine, also introduced another inhalation preparation about to be approved by Healthy Yuan Group at the meeting—"Lishutong" (salbutamol hydrochloride nebulized inhalation solution). It is the first new Class 3 registered and approved nebulized inhalation solution in China, which means that "Lishutong" will also become the first salbutamol to be launched in China. Compared with the imported or domestic salbutamol already on the market in China, "Lishutong" has the characteristics of small dosage, high efficacy, and high safety. This another "first" for Healthy Yuan Group means that it will continue to provide Chinese doctors with more and better choices, benefiting more asthma and chronic obstructive pulmonary disease patients, and also demonstrating Healthy Yuan Group's confidence and strength in the field of inhalation preparations. Currently, Healthy Yuan Group is on the eve of an outbreak in the respiratory inhalation preparation market, and the biopharmaceutical business of its subsidiary Lizhu Group is also experiencing explosive growth. It is believed that after "Shutanlin" and "Lishutong," Healthy Yuan Group will become increasingly stable in the innovation and R&D of inhalation preparations. The series of inhalation preparation products about to be launched in the future are also highly anticipated! Source: Sohu.com
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.